# Prevalence and Risk Factors of Reduced Bone Mineral Density in Systemic Lupus Erythematosus Patients: A Meta-Analysis

Authors: Jumei Xia; Ran Luo; Shuiming Guo; Yi Yang; Shuwang Ge; Gang Xu; Rui Zeng
Journal: BioMed Research International
 (2019)

---

## Abstract

Background. We aimed to conduct a meta-analysis concerning the frequency and risk factors of reduced bone mineral density (BMD) in systemic lupus erythematosus (SLE) with evidence from published studies.Methods. A comprehensive literature search was conducted based on the EMBASE, Web of Science, PubMed, and Cochrane Library databases up to March 5th, 2017. Eligible studies reported any prevalence of reduced BMD in SLE patients. All risk factors with odds ratios or risk ratios associated with reduced BMD were extracted.Results. 71 reports with 33527 SLE patients were included. Low BMD, osteopenia, and osteoporosis at any site were presented, respectively, in 45%, 38%, and 13% of the SLE patients. The prevalence of osteoporosis increased with the advancing of age, while U-shaped associations between age and the prevalence of low BMD and osteopenia were found. Lumbar spine was indicated to have higher prevalence of osteoporosis. Age, disease duration, drugs use, and many other factors were identified as predictors of reduced BMD.Conclusion. Low BMD, osteoporosis, and osteopenia appeared to be prevalent in patients with SLE. Risk factors of reduced BMD were various.


---

## Body

## 1. Introduction

Nowadays the long-term complications of systemic lupus erythematosus (SLE) have become great concerns as the survival of SLE has improved dramatically [1]. Publications have shown that patients with SLE have an increased risk of developing reduced bone mineral density (BMD) [2, 3]. The frequency of osteopenia according to WHO criteria is reported to be from 24% to 74% [4, 5] and osteoporosis is from 1.4% to 68.7% [3, 6, 7] in SLE patients. However, most of them are single-center studies and the outcomes vary widely.Risk factors associated with decreased BMD are still under debate in SLE patients. SLE occurs commonly in females [8, 9]. Women are known to have high prevalence of osteoporosis and osteoporotic fractures [10]. Long-term use of corticosteroid, immunosuppressives, and other drugs, SLE disease damage, and menopause status all might have an effect on bone loss. Osteoporosis is a prevalent complication of SLE and it may lead to increased morbidity and mortality [11, 12]. The reported risk factors from different studies differ greatly [13–15].The aim of this study was to conduct a meta-analysis concerning the frequency and risk factors of osteopenia, osteoporosis, or low BMD in SLE patients with evidence from published studies.


## 2. Materials and Methods

This study was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) Checklist [16] (Supplementary 1. S1 file).


### 2.1. Literature Search Strategy

We performed a comprehensive literature search based on the PubMed, Web of Science, Cochrane Library, and EMBASE up to March 5th, 2017. We used the keywords including “(Systemic Lupus Erythematosus or SLE)” and “(risk factors or outcomes or Prevalence)” and “(bone mineral density or bone density or Osteoporosis or Osteopenia or Fracture)” (Supplementary2. S2 file). Moreover, we hand-searched the reference lists of all identified eligible papers and relevant narrative reviews for additional relevant studies. Titles and abstracts were screened to identify potentially relevant studies; of these, full texts were reviewed. The full text of an article was assessed if there was any doubt to the eligibility of it. Two of the authors (Y.Y. and J.M.X) independently undertook literature search and study selection using a standardized approach. Reviewers were not blinded to study authors or outcomes. Any inconsistencies were resolved by discussion or by consulting a third author (S.W.G.).


### 2.2. Inclusion and Exclusion Criteria

We included published original articles and data on prevalence of decreased bone density, osteoporosis, or osteopenia in SLE patients. There was no restriction of language. Letter, review, conference abstract, editorial material, comment, case report, meta-analysis, and book chapter were excluded. If two articles from the same population reported different data, we included both of them. Otherwise, if the articles reported the same prevalence, we included the article with the larger sample size. In a longitudinal study that reported prevalence of decreased bone density in different time points, we included the baseline data.


### 2.3. Data Extraction

We extracted the information of interest by two authors (Y.Y. and J.M.X) from each study including study characteristics (study group name, publication year, sample size, age at baseline, female%, SLEDAI, SLICCR/ACR/SDI, BMI, proportion of postmenopausal status, proportion of corticosteroid ever user, mean cumulative corticosteroid dose, age at disease onset, SLE duration, and SLE diagnostic criteria) and any prevalence (data to calculate it) of low BMD (defined as the prevalence of low BMD, or the sum of osteoporosis and osteopenia, or 100%-normal; or if only osteoporosis or osteopenia was reported, defined as the prevalence of osteoporosis or osteopenia) in SLE patients at any part of body. We classified the prevalence according to different sites and different degree of decreased bone density. If a study measured three or more sites of any one patient and gave whole prevalence of osteoporosis, osteopenia, or low BMD for this population or reported the prevalence without stating the sites, we classified this prevalence as “at any site.”


### 2.4. Statistical Analysis

Heterogeneity of prevalence across included studies was examined usingχ2 based on Q-statistical test and quantified by I2 index. Roughly, heterogeneity was considered significant at P<0.10 and Higgins I2 values of 25%, 50%, and 75% were considered low, moderate, and high inconsistencies. Results of studies were pooled by random-effects models in the presence of high heterogeneity among our studies. All analyses and graphs were made using Stata 10.0 (College Station, TX, USA) and GraphPad Prism 6. P values < 0.05 by two-tailed test were considered significant.


## 2.1. Literature Search Strategy

We performed a comprehensive literature search based on the PubMed, Web of Science, Cochrane Library, and EMBASE up to March 5th, 2017. We used the keywords including “(Systemic Lupus Erythematosus or SLE)” and “(risk factors or outcomes or Prevalence)” and “(bone mineral density or bone density or Osteoporosis or Osteopenia or Fracture)” (Supplementary2. S2 file). Moreover, we hand-searched the reference lists of all identified eligible papers and relevant narrative reviews for additional relevant studies. Titles and abstracts were screened to identify potentially relevant studies; of these, full texts were reviewed. The full text of an article was assessed if there was any doubt to the eligibility of it. Two of the authors (Y.Y. and J.M.X) independently undertook literature search and study selection using a standardized approach. Reviewers were not blinded to study authors or outcomes. Any inconsistencies were resolved by discussion or by consulting a third author (S.W.G.).


## 2.2. Inclusion and Exclusion Criteria

We included published original articles and data on prevalence of decreased bone density, osteoporosis, or osteopenia in SLE patients. There was no restriction of language. Letter, review, conference abstract, editorial material, comment, case report, meta-analysis, and book chapter were excluded. If two articles from the same population reported different data, we included both of them. Otherwise, if the articles reported the same prevalence, we included the article with the larger sample size. In a longitudinal study that reported prevalence of decreased bone density in different time points, we included the baseline data.


## 2.3. Data Extraction

We extracted the information of interest by two authors (Y.Y. and J.M.X) from each study including study characteristics (study group name, publication year, sample size, age at baseline, female%, SLEDAI, SLICCR/ACR/SDI, BMI, proportion of postmenopausal status, proportion of corticosteroid ever user, mean cumulative corticosteroid dose, age at disease onset, SLE duration, and SLE diagnostic criteria) and any prevalence (data to calculate it) of low BMD (defined as the prevalence of low BMD, or the sum of osteoporosis and osteopenia, or 100%-normal; or if only osteoporosis or osteopenia was reported, defined as the prevalence of osteoporosis or osteopenia) in SLE patients at any part of body. We classified the prevalence according to different sites and different degree of decreased bone density. If a study measured three or more sites of any one patient and gave whole prevalence of osteoporosis, osteopenia, or low BMD for this population or reported the prevalence without stating the sites, we classified this prevalence as “at any site.”


## 2.4. Statistical Analysis

Heterogeneity of prevalence across included studies was examined usingχ2 based on Q-statistical test and quantified by I2 index. Roughly, heterogeneity was considered significant at P<0.10 and Higgins I2 values of 25%, 50%, and 75% were considered low, moderate, and high inconsistencies. Results of studies were pooled by random-effects models in the presence of high heterogeneity among our studies. All analyses and graphs were made using Stata 10.0 (College Station, TX, USA) and GraphPad Prism 6. P values < 0.05 by two-tailed test were considered significant.


## 3. Results

### 3.1. Study Search and Basic Characteristics

We identified 1233 articles by systematic electronic searches; 70 of those were eligible for this meta-analysis. And 1 study was included through hand-searching the reference lists of all identified eligible papers (flow diagram for selection of studies as Figure1). References and characteristics of studies included in this meta-analysis were listed in Supplementary 3. S3 file and Supplementary 4. S4 file, respectively. 33527 SLE patients (female: 90.2%, postmenopausal: 31.6%) with an overall average age of 43.5 years were eligible for inclusion. The mean disease duration was 8.5 years, the mean SLEDAI score was 4.7, and mean SLICC damage index was 1.1. Percentage of steroids ever used was demonstrated in 36 studies and the mean percentage was 78.8%. Mean cumulative dose of steroids was 20.6 gram. More than half the studies (38/71) were published after 2010. Of the included studies, prevalence of low BMD, osteopenia, and osteoporosis was, respectively, reported in 57, 60, and 46 studies; decreased prevalence of bone density of lumbar spine, femur, total hip, and any one site was respectively reported in 32, 20, 22, and 52 studies.Figure 1
Flow chart of the systematic review.


### 3.2. Prevalence of Decreased Bone Density in Different Sites and Patients

The pooled prevalence of low BMD, osteopenia, and osteoporosis at different skeletal sites for all patients and postmenopausal and premenopausal patients was represented in Table1. The heterogeneity was high for most of the subgroup analyses. The prevalence of low BMD, osteopenia, and osteoporosis was 45% (38, 51), 38% (31, 45), and 13% (11, 16), respectively. Compared to premenopausal patients, postmenopausal patients had relatively higher prevalence of low BMD in all sites. Lumbar spine was indicated to have higher prevalence of osteoporosis.Table 1
Meta-analysis of the prevalence of osteopenia, osteoporosis, and low BMD in all SLE patients and postmenopausal and premenopausal patients.
Variable All patients Premenopausal patients Postmenopausal patients Number of studies Sample size Prevalence(95% CI) I2 Number of studies Sample size Prevalence(95% CI) I2 Number of studies Sample size Prevalence(95% CI) I2 Osteopenia Spine 26 2951 35% (33, 38) 51.8% 4 264 29% (22, 37) 45.7% 4 189 37% (30, 44) 0.0% Femur 15 1290 43% (38, 47) 66.0% 3 164 24% (17, 31) 0.0% 4 189 53% (38, 68) 74.8% Total hip 15 2293 35% (27, 42) 92.7% 2 174 16% (11, 20) 0.0% 2 122 53% (26, 80) 88.0% Any site 34 3319 38% (31, 45) 95.2% 8 502 42% (31, 52) 85.1% 3 234 25% (2, 48) 95.7% Osteoporosis Spine 28 3317 13% (10, 15) 86.8% 9 512 13% (7, 19) 83.5% 4 189 27% (16, 37) 61.7% Femur 15 1389 6% (5, 8) 8.0% 4 234 5% (2, 8) 4.2% 4 189 7% (2, 13) 54.3% Total hip 15 2078 4% (3, 5) 63.7% 2 174 1% (-0, 3) 0.0% 2 122 12% (6, 18) 0.0% Any site 42 29543 13% (11, 16) 90.8% 10 613 9% (5, 12) 73.0% 3 234 21% (11, 31) 74.0% Low BMD Spine 29 3283 48% (43, 53) 89.2% 9 552 43% (32, 55) 88.9% 3 171 71% (56, 86) 79.2% Femur 18 1602 47% (35, 59) 96.6% 5 257 39% (27, 51) 75.6% 4 189 61% (51, 71) 50.8% Total hip 19 2686 36% (26, 46) 97.4% 4 301 16% (11, 20) 23.0% 2 122 65% (43, 83) 84.0% Any site 40 5171 45% (38, 51) 96.6% 16 1179 40% (29, 51) 95.1% 2 153 43% (22, 63) 86.0%


### 3.3. Exploring the Potential Risk Factors

Figure2 showed the three models of prevalence by age for osteoporosis, osteopenia, and low BMD at any site. The prevalence of osteoporosis increased with the advancing of age, while U-shaped associations between age and the prevalence of low BMD and osteopenia were found. Age might have influence on bone health.Figure 2
Prevalence of osteoporosis, osteopenia, and low BMD at any site by age for all SLE patients from the literature search.The association between potential risk factors and low BMD, osteoporosis, and fracture in SLE patients from the literature search was shown in Table2. Postmenopausal status, non-Afro-Caribbean, higher BMI z score, number of deliveries, ever taken prednisolone >10 mg/day, and maximal dosage of >50 mg/day of oral corticosteroids were significantly associated with low BMD, while menopause, disease duration, and prednisone use were associated with osteoporosis. The risk factors for fractures were disease duration, taken osteoporosis medications, age, higher BMI, history of previous bone fracture, corticosteroids use, seizures, cerebrovascular events, and SLICC/ACR-DI.Table 2
Risk factors for reduced bone mineral density in patients with SLE from the literature search.
Study (first author, year) Country Study design Size Female (%) Mean age (y) Outcome Risk factor Estimate (aOR, 95% CI) LAKSHMINARAYANAN et al. 2001 USA Prospective cohort 92 100 32.8 Low BMD Menopause 3.32 (1.45, 7.62) Yee et al. 2004 UK Case control 242 95.5 39.9 Low BMD Non-Afro-Caribbeanever taken prednisolone >10 mg/day 2.5 (1.2, 5.4)2.1 (1.1, 4.2) LEE et al. 2007 USA Case control 298 100 42.1 Low hip BMD African American raceAge at SLE diagnosisBMIDrink caffeineSDISLE renal diseaseCurrent use of GCStudy center 1.54 (0.69, 3.46)0.98 (0.95, 1.01)0.90 (0.84, 0.96)1.33 (0.53, 3.36)1.30 (1.08, 1.57)0.79 (0.33, 1.87)1.48 (0.71, 3.09)0.95 (0.42, 2.15) LEE et al. 2007 USA Case control 298 100 42.1 Low lumbar spine BMD African American raceAge at SLE diagnosisBMI/ kg/m2Drink caffeineSDISLE renal diseaseCurrent use of GCStudy center 4.42 (2.19, 8.91)0.96 (0.93, 0.99)0.93 (0.89, 0.98)0.34 (0.17, 0.72)1.06 (0.89, 1.26)1.50 (0.71, 3.16)1.54 (0.81, 2.92)0.71 (0.33, 1.53) Furukawa et al. 2011 Japan Case control 58 100 44.0 Low BMD Number of deliveriesMaximal dosage of >50 mg/day of oral GC 5.58 (1.31, 26.06)0.25 (0.07, 0.91) Lim et al. 2011 Canada Retrospective cohort 80 82.5 14.2a Low BMD Higher BMI z score 0.35 (0.18, 0.69) Bonfá et al. 2015 Brazil Case control 365 100 32.8 Low BMD Current GC useOsteoprotegerin 245 T>G 3.97 (1.51, 10.41)2.14 (1.02, 4.50) Seguro et al. 2015 Brazil Prospective cohort 63 100 31.1 Low BMD NPT1Cumulative GCMean GCMaximum GC 1.03 (1.01–1.05)1.00 (1.00–1.00)1.0 (0.95, 1.04)0.98 (0.95, 1.01) Cramarossa et al. 2016 Canada Prospective cohort 286 88.8 38.0 Low BMD AgeFemaleCumulative ACR criteriaSDI excluding OsteoporosisVitamin D useCalcium useBisphosphonates use Immunosuppressives useCumulative GC dose 1.06 (1.04, 1.08)​∗0.47 (0.23, 1.00)​∗0.80 (0.63, 1.02)​∗1.43 (1.12, 1.82) ​∗1.63 (0.94, 2.80) ​∗1.63 (0.94, 2.80) ​∗1.72 (0.85, 3.47) ​∗1.51 (0.90, 2.52)1.04 (1.01, 1.07) Lacassagne et al. 2007 Canada Prospective cohort 64 76.6 14.3 Osteopenia Cumulative GC dose 1.003 (1.001, 1.01) Mak et al. 2011 Singapor Case control 110 87 40.5 Osteopenia Disease duration/monthBMI/kg/m2Cyclosporine useCumulative GC doseFMD/%Carotid IMT/mm 1.031 (0.99, 1.0730.78 (0.53, 1.16)0.014 (0.00, 1.01)1.080 (0.85, 1.38)0.147 (0.02, 0.96)0.000 (0.000) SINIGAGLIA et al. 1999 Italy Case control 84 100 30.5 Osteoporosis Disease duration/yearPrednisone/year-use 1.2 (1.07, 1.33)1.16 (1.05, 1.29) Banno et al. 2002 Japan Case control 60 100 34.8 Osteoporosis Cumulative GC intake 1.06 (1.01, 1.11) Yee et al. 2004 UK Case control 242 95.5 39.9 Osteoporosis MenopauseAge/year 13.3 (1.6, 111.1)1.0 (1.0, 1.1) Lacassagne et al. 2007 Canada Prospective cohort 64 76.6 14.3 Osteoporosis Disease duration/yearlupus nephritis 1.60 (1.18, 2.18)8.79 (0.96, 80.24) Crosslin et al. 2011 USA Case control 14829 90.5 47.3 Osteoporosis Male 0.65 (0.43, 0.97) Ajeganova et al. 2015 Sweden Case control 222 89 48.7 Osteoporosis Carotid plaque 1.78 (0.97, 3.24) Note: OR, odds ratio; USA, United States of America; BMD, bone mineral density; UK, the United Kingdom of Great Britain and Northern Ireland; BMI, Body mass index; SLICC/ACR-DI, the Systemic Lupus International Collaborating Clinics/American College of Rheumatology-Damage Index; GC, glucocorticoid; NPT1, N-terminal propeptide of type 1 collagen; FMD, flow-mediated dilatation. Hint:mediana; ​∗aRR: adjusted risk ratio.


## 3.1. Study Search and Basic Characteristics

We identified 1233 articles by systematic electronic searches; 70 of those were eligible for this meta-analysis. And 1 study was included through hand-searching the reference lists of all identified eligible papers (flow diagram for selection of studies as Figure1). References and characteristics of studies included in this meta-analysis were listed in Supplementary 3. S3 file and Supplementary 4. S4 file, respectively. 33527 SLE patients (female: 90.2%, postmenopausal: 31.6%) with an overall average age of 43.5 years were eligible for inclusion. The mean disease duration was 8.5 years, the mean SLEDAI score was 4.7, and mean SLICC damage index was 1.1. Percentage of steroids ever used was demonstrated in 36 studies and the mean percentage was 78.8%. Mean cumulative dose of steroids was 20.6 gram. More than half the studies (38/71) were published after 2010. Of the included studies, prevalence of low BMD, osteopenia, and osteoporosis was, respectively, reported in 57, 60, and 46 studies; decreased prevalence of bone density of lumbar spine, femur, total hip, and any one site was respectively reported in 32, 20, 22, and 52 studies.Figure 1
Flow chart of the systematic review.


## 3.2. Prevalence of Decreased Bone Density in Different Sites and Patients

The pooled prevalence of low BMD, osteopenia, and osteoporosis at different skeletal sites for all patients and postmenopausal and premenopausal patients was represented in Table1. The heterogeneity was high for most of the subgroup analyses. The prevalence of low BMD, osteopenia, and osteoporosis was 45% (38, 51), 38% (31, 45), and 13% (11, 16), respectively. Compared to premenopausal patients, postmenopausal patients had relatively higher prevalence of low BMD in all sites. Lumbar spine was indicated to have higher prevalence of osteoporosis.Table 1
Meta-analysis of the prevalence of osteopenia, osteoporosis, and low BMD in all SLE patients and postmenopausal and premenopausal patients.
Variable All patients Premenopausal patients Postmenopausal patients Number of studies Sample size Prevalence(95% CI) I2 Number of studies Sample size Prevalence(95% CI) I2 Number of studies Sample size Prevalence(95% CI) I2 Osteopenia Spine 26 2951 35% (33, 38) 51.8% 4 264 29% (22, 37) 45.7% 4 189 37% (30, 44) 0.0% Femur 15 1290 43% (38, 47) 66.0% 3 164 24% (17, 31) 0.0% 4 189 53% (38, 68) 74.8% Total hip 15 2293 35% (27, 42) 92.7% 2 174 16% (11, 20) 0.0% 2 122 53% (26, 80) 88.0% Any site 34 3319 38% (31, 45) 95.2% 8 502 42% (31, 52) 85.1% 3 234 25% (2, 48) 95.7% Osteoporosis Spine 28 3317 13% (10, 15) 86.8% 9 512 13% (7, 19) 83.5% 4 189 27% (16, 37) 61.7% Femur 15 1389 6% (5, 8) 8.0% 4 234 5% (2, 8) 4.2% 4 189 7% (2, 13) 54.3% Total hip 15 2078 4% (3, 5) 63.7% 2 174 1% (-0, 3) 0.0% 2 122 12% (6, 18) 0.0% Any site 42 29543 13% (11, 16) 90.8% 10 613 9% (5, 12) 73.0% 3 234 21% (11, 31) 74.0% Low BMD Spine 29 3283 48% (43, 53) 89.2% 9 552 43% (32, 55) 88.9% 3 171 71% (56, 86) 79.2% Femur 18 1602 47% (35, 59) 96.6% 5 257 39% (27, 51) 75.6% 4 189 61% (51, 71) 50.8% Total hip 19 2686 36% (26, 46) 97.4% 4 301 16% (11, 20) 23.0% 2 122 65% (43, 83) 84.0% Any site 40 5171 45% (38, 51) 96.6% 16 1179 40% (29, 51) 95.1% 2 153 43% (22, 63) 86.0%


## 3.3. Exploring the Potential Risk Factors

Figure2 showed the three models of prevalence by age for osteoporosis, osteopenia, and low BMD at any site. The prevalence of osteoporosis increased with the advancing of age, while U-shaped associations between age and the prevalence of low BMD and osteopenia were found. Age might have influence on bone health.Figure 2
Prevalence of osteoporosis, osteopenia, and low BMD at any site by age for all SLE patients from the literature search.The association between potential risk factors and low BMD, osteoporosis, and fracture in SLE patients from the literature search was shown in Table2. Postmenopausal status, non-Afro-Caribbean, higher BMI z score, number of deliveries, ever taken prednisolone >10 mg/day, and maximal dosage of >50 mg/day of oral corticosteroids were significantly associated with low BMD, while menopause, disease duration, and prednisone use were associated with osteoporosis. The risk factors for fractures were disease duration, taken osteoporosis medications, age, higher BMI, history of previous bone fracture, corticosteroids use, seizures, cerebrovascular events, and SLICC/ACR-DI.Table 2
Risk factors for reduced bone mineral density in patients with SLE from the literature search.
Study (first author, year) Country Study design Size Female (%) Mean age (y) Outcome Risk factor Estimate (aOR, 95% CI) LAKSHMINARAYANAN et al. 2001 USA Prospective cohort 92 100 32.8 Low BMD Menopause 3.32 (1.45, 7.62) Yee et al. 2004 UK Case control 242 95.5 39.9 Low BMD Non-Afro-Caribbeanever taken prednisolone >10 mg/day 2.5 (1.2, 5.4)2.1 (1.1, 4.2) LEE et al. 2007 USA Case control 298 100 42.1 Low hip BMD African American raceAge at SLE diagnosisBMIDrink caffeineSDISLE renal diseaseCurrent use of GCStudy center 1.54 (0.69, 3.46)0.98 (0.95, 1.01)0.90 (0.84, 0.96)1.33 (0.53, 3.36)1.30 (1.08, 1.57)0.79 (0.33, 1.87)1.48 (0.71, 3.09)0.95 (0.42, 2.15) LEE et al. 2007 USA Case control 298 100 42.1 Low lumbar spine BMD African American raceAge at SLE diagnosisBMI/ kg/m2Drink caffeineSDISLE renal diseaseCurrent use of GCStudy center 4.42 (2.19, 8.91)0.96 (0.93, 0.99)0.93 (0.89, 0.98)0.34 (0.17, 0.72)1.06 (0.89, 1.26)1.50 (0.71, 3.16)1.54 (0.81, 2.92)0.71 (0.33, 1.53) Furukawa et al. 2011 Japan Case control 58 100 44.0 Low BMD Number of deliveriesMaximal dosage of >50 mg/day of oral GC 5.58 (1.31, 26.06)0.25 (0.07, 0.91) Lim et al. 2011 Canada Retrospective cohort 80 82.5 14.2a Low BMD Higher BMI z score 0.35 (0.18, 0.69) Bonfá et al. 2015 Brazil Case control 365 100 32.8 Low BMD Current GC useOsteoprotegerin 245 T>G 3.97 (1.51, 10.41)2.14 (1.02, 4.50) Seguro et al. 2015 Brazil Prospective cohort 63 100 31.1 Low BMD NPT1Cumulative GCMean GCMaximum GC 1.03 (1.01–1.05)1.00 (1.00–1.00)1.0 (0.95, 1.04)0.98 (0.95, 1.01) Cramarossa et al. 2016 Canada Prospective cohort 286 88.8 38.0 Low BMD AgeFemaleCumulative ACR criteriaSDI excluding OsteoporosisVitamin D useCalcium useBisphosphonates use Immunosuppressives useCumulative GC dose 1.06 (1.04, 1.08)​∗0.47 (0.23, 1.00)​∗0.80 (0.63, 1.02)​∗1.43 (1.12, 1.82) ​∗1.63 (0.94, 2.80) ​∗1.63 (0.94, 2.80) ​∗1.72 (0.85, 3.47) ​∗1.51 (0.90, 2.52)1.04 (1.01, 1.07) Lacassagne et al. 2007 Canada Prospective cohort 64 76.6 14.3 Osteopenia Cumulative GC dose 1.003 (1.001, 1.01) Mak et al. 2011 Singapor Case control 110 87 40.5 Osteopenia Disease duration/monthBMI/kg/m2Cyclosporine useCumulative GC doseFMD/%Carotid IMT/mm 1.031 (0.99, 1.0730.78 (0.53, 1.16)0.014 (0.00, 1.01)1.080 (0.85, 1.38)0.147 (0.02, 0.96)0.000 (0.000) SINIGAGLIA et al. 1999 Italy Case control 84 100 30.5 Osteoporosis Disease duration/yearPrednisone/year-use 1.2 (1.07, 1.33)1.16 (1.05, 1.29) Banno et al. 2002 Japan Case control 60 100 34.8 Osteoporosis Cumulative GC intake 1.06 (1.01, 1.11) Yee et al. 2004 UK Case control 242 95.5 39.9 Osteoporosis MenopauseAge/year 13.3 (1.6, 111.1)1.0 (1.0, 1.1) Lacassagne et al. 2007 Canada Prospective cohort 64 76.6 14.3 Osteoporosis Disease duration/yearlupus nephritis 1.60 (1.18, 2.18)8.79 (0.96, 80.24) Crosslin et al. 2011 USA Case control 14829 90.5 47.3 Osteoporosis Male 0.65 (0.43, 0.97) Ajeganova et al. 2015 Sweden Case control 222 89 48.7 Osteoporosis Carotid plaque 1.78 (0.97, 3.24) Note: OR, odds ratio; USA, United States of America; BMD, bone mineral density; UK, the United Kingdom of Great Britain and Northern Ireland; BMI, Body mass index; SLICC/ACR-DI, the Systemic Lupus International Collaborating Clinics/American College of Rheumatology-Damage Index; GC, glucocorticoid; NPT1, N-terminal propeptide of type 1 collagen; FMD, flow-mediated dilatation. Hint:mediana; ​∗aRR: adjusted risk ratio.


## 4. Discussion

In the current meta-analysis, as expected, the prevalence of low BMD at any site in SLE patients was high (45%), no matter in premenopausal patients (40%) or in postmenopausal patients (43%). The prevalence of osteopenia in all patients and premenopausal patients and postmenopausal patients was 38%, 42%, and 25%, while prevalence of osteoporosis was 13%, 9%, and 21%, respectively.Higher prevalence of osteoporosis was shown at lumbar spine (13%) compared with the femur (6%) and hip (4%) in our study, which was consistent with some observational studies [2, 3, 17]. Lumbar spine was also reported to have high risk of fracture in SLE patients [9]. The mechanism for this discrepancy might be due to the widespread use of glucocorticoids for SLE therapy and the variable composition of each bone [18]. Trabecular bone is mainly affected by intensive glucocorticoid treatment [19], and the lumbar spine is mainly composed of trabecular bone. Low BMD and fracture of lumbar spine might have disastrous consequences. So, enough attention, timely examination, and effective intervention should be given to the bone density for SLE patients.Several factors may explain the prevalence of low BMD in SLE patients.First, SLE was a chronic autoimmune disease with multiorgan inflammation. The mean disease duration of SLE was 8.5 years and the mean SLEDAI score was 4.6 in our analysis. There were many disease-related variables playing a role in bone health. Increasing of tumor necrosis factor-α [20], interleukin-6 [21], and interleukin-1 [22] in the serum had an effect on the stimulation of bone resorption and inhibition of bone formation [23].Second, corticosteroid therapy was frequent among SLE patients. From our literature search, the percentage of corticosteroid use was reported to be from 51.6% [24] to 100% [25, 26] (mean percentage: 78.8%; mean cumulative dose: 20.6 gram) and glucocorticoid use was reported to be associated with fractures [14, 27], osteoporosis [28, 29], and low BMD [30–32] in SLE patients. The mechanism might be that corticosteroid could inhibit the formation and function of osteoblast [33, 34], increase osteoclast, and inhibit absorption of calcium [35, 36], as well as affecting glucocorticoid induced leucine zipper proteins [37], 11β-hydroxysteroid dehy- drogenase type 1 [38], and other associated proteins to induce bone loss.Third, postmenopausal status could lead to bone loss. In our study, postmenopausal patients (31.6% of all patients) showed higher prevalence of osteopenia, osteoporosis, and low BMD in almost all sites. Most of our SLE patients undergo early menopause, which may be due to SLE disease per se or its treatment with cytotoxic substances [39, 40]. Postmenopausal status was known as a risk factor of bone loss because of lacking estrogen, which affected the balance of bone formation and resorption metabolism through series of receptors and cytokines [41–45]. Postmenopausal status was reported to be associated with increased risk of low BMD (adjusted OR=3.32, 95% CI: 1.45-7.62) [46] and osteoporosis (adjusted OR=13.3, 95% CI: 1.6-111.1) [31]. Hence, it was necessary to place emphasis on the bone health for postmenopausal SLE patients.Fourth, degeneration of bone increased with age. Older age was independently associated with bone loss in both general population [47] and SLE patients [2, 31]. Older age was also reported to be related to fracture [14, 48]. The overall average age of our included patients was 43.5 years and prevalence of osteoporosis increased with age. U-shaped associations between age and the prevalence of low BMD and osteopenia were found. For early-onset lupus and young patients, other factors, such as higher SLE disease index and inflammatory disease itself [49, 50], might influence the bone health. Similarly, we found that SLEDAI increased with the decreasing of age. In a word, age and SLE disease might affect the bone health at the same time.Other risk factors might have effects on bone health in SLE patients. (1) The use of antimalarials might influence cytokines, lysosomal membranes, DNA, antigen processing, and other mechanisms that might lead to loss of bone. (2) The effect of body mass index (BMI) was still under debate. It was reported to be associated with increased risk of vertebral fracture (adjusted OR=1.17, 95% CI: 1.02-1.33) [48], but Lee et al. did not obtain the association with fracture (adjusted OR=1.01, 95% CI: 0.952-1.07) [12]. Meanwhile, higher BMI z score was associated with decreased risk of low BMD (adjusted OR=1.17, 95% CI: 1.02-1.33). More well-designed studies were needed to explore the association between BMI and bone loss. (3) Race, disease duration, the Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index, and many other risk factors were all reported to have associated with bone loss or fracture [27, 28, 31, 51].We acknowledged some limitations of our analyses. Firstly, BMD measurements were performed in SLE patients with different disease duration. Secondly, the treatments for patients varied greatly. Thirdly, the differences regarding race, genetics, geographical locations, and lifestyle across the different population studied were not well considered. Fourthly, few studies reported the bone condition in male SLE patients, so we failed to extrapolate gender-related differences. Finally, the heterogeneity was high for most of the analyses.


## 5. Conclusions

SLE patients were at a great risk of developing low BMD, especially in lumbar spine and the postmenopausal patients. The risk factors that associated with low BMD might include low body weight, menopause duration, age, and disease-related factors.



---

*Source: 3731648-2019-02-20.xml*